adx-324
Nucleic acidexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Dec 14, 2022 (NCT05691361)
Timeline
Indications
Studied for
Mechanism of action
- Plasma kallikreinANTISENSE INHIBITOR
KLKB1 antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06960213 | Phase 3 | Aug 28, 2025 | ADARx Pharmaceuticals, Inc. |
| NCT05691361 | Phase 1 | Dec 14, 2022 | ADARx Pharmaceuticals, Inc., CMAX Clinical Research |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ADARx Pharmaceuticals, Inc. | For profit | 2 | 2 | 2 | 2022 |
| CMAX Clinical Research | For profit | 1 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1